The similar prognostic impact of DOCK1 expression was also present in the patients with AML other than acute promyelocytic leukemia (Figure 2E) as well as cytogenetically normal AML (Figure 2F) in our cohort. This evidence concerns the gene DOCK1 and acute promyelocytic leukemia.